TRIAL OF SIMVASTATIN TO SLOW THE PROGRESSION OF ALZHEIMER'S DISEASE

这个子项目是利用由NIH/NCRR资助的中心拨款提供的资源的许多研究子项目之一。子项目和调查员(PI)可能从另一个NIH来源获得了主要资金，因此可能会出现在其他CRISE条目中。列出的机构是针对中心的，而不一定是针对调查员的机构。这项研究的目的是确定与安慰剂相比，辛伐他汀在降低胆固醇水平和治疗或减缓AD进展方面的安全性、耐受性和有效性。辛伐他汀是食品和药物协会批准的一种药物，用于降低血液中的胆固醇水平，治疗心脏病，降低心脏病发作、中风和死亡的风险。辛伐他汀治疗阿尔茨海默病是实验性的。来自该机构的10至15名受试者预计将参与这项研究

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. The purpose of this study is to determine the safety,tolerability and effectiveness of Simvastatin in lowering cholesterol levels and treating or slowing the progression of AD when compared to a placebo. Simvastatin is a Food and Drug Association approved drug used to lower cholesterol levels in the blood, treat heart conditions and reduce the risk of heart attack,stroke and death. The use of Simvastatin for Alzheimer's Disease is experimental. Ten to fifteen subjects from this facility are expected to participate in this study